; Juniper Pharmaceuticals | Investor Relations Overview

Investor Relations Overview

Corporate Profile

Juniper Pharmaceuticals (Nasdaq: JNP) is developing therapeutics that address unmet and underserved medical needs in women's health. Our current product pipeline leverages our highly differentiated intravaginal ring ("IVR") technology with new formulations of existing pharmaceuticals, which we expect will offer multiple benefits to patients. Current 505(b)(2) candidates include:

  • JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women;
  • JNP-0201, a combination estradiol + progesterone IVR for hormone replacement therapy; and,
  • JNP-0301, a natural progesterone IVR for the prevention of preterm birth.

We are leveraging the in-hous  More >>

Stock Quote

JNP (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Change (%) Stock is Up 0.05 (0.96%)
Data as of 11/22/17 3:58 p.m. ET
Minimum 20 minute delayRefresh quote
Recent NewsMore >>
11/02/17Juniper Pharmaceuticals Reports Third Quarter 2017 Financial and Operating ResultsPrinter Friendly Version
10/26/17Juniper Pharmaceuticals to Report Third Quarter 2017 Results on November 2, 2017Printer Friendly Version
09/18/17Juniper Pharmaceuticals Announces Strategic ReprioritizationPrinter Friendly Version
09/11/17Juniper Pharmaceuticals Appoints Jennifer Good to Board of DirectorsPrinter Friendly Version